MT1HL1

Across TCGA pan-cancer cohorts, MT1HL1 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated MT1HL1 data layer compared with 9 for mutation status.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher MT1HL1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MT1HL1 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

CHOL, HNSC, and BLCA are the cancer types where MT1HL1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.089	0.718	<.001	87	view →
HNSC	DFS	Tertile	IV	0.320	0.640	<.001	60	view →
BLCA	OS	Tertile	III,IV	0.416	0.594	.013	54	view →
STAD	OS	Tertile	IV	0.565	0.159	.011	45	view →
COAD	DFS	Tertile	IV	0.286	0.547	.004	45	view →
ACC	OS	Tertile	III,IV	0.311	0.789	.002	45	view →
KIRC	DFS	Median	All	0.533	0.679	<.001	43	view →
UCEC	OS	Median	IV	0.838	0.365	<.001	36	view →
KICH	OS	Quartile	II,III,IV	0.370	0.913	<.001	35	view →
SKCM	OS	Tertile	III,IV	0.649	0.344	.004	27	view →
MESO	OS	Tertile	All	0.611	0.219	.026	24	view →
THCA	OS	Quartile	II,III,IV	0.893	0.966	.025	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

MT1HL1–CHOL (OS)

Open the CHOL breakdown →